CuraTech nominated Finalist in the Diabetes Australia Grand Innovation Challenge 2026
22 June 2026
We are incredibly proud that CuraTech and Surgical BioFix - with REVITA - have been selected as one of just 10 finalists in the Diabetes Australia Grand Innovation Challenge 2026!
Around 50,000 Australians experience a diabetic foot ulcer each year, often with a devastating impact on their quality of life and a significant burden on our healthcare system. When standard wound care isnβt enough, clinicians and patients urgently need another option.
π₯ππ©ππ§π is an innovative, Australian-produced placental membrane allograft designed to support healing when difficult-to-heal wounds have stalled. Early clinical results are encouraging, and the Grand Innovation Challenge could help us build the robust Australian clinical and health-economic evidence needed to bring this innovation to more patients.
Because better healing could mean fewer infections, fewer hospital stays, fewer amputations β and a profound difference for patients and their families.
We are thrilled to be among the finalists and look forward to presenting π₯ππ©ππ§π at the Grand Final at the Diabetes Community Day at the IDF-WPR Congress 2026!
